Why Rocket Pharma Is Rising In Pre-market?
(RTTNews) - Rocket Pharmaceuticals, Inc. (RCKT) announced the FDA has accepted the resubmission of the Biologics License Application for KRESLADI or marnetegragene autotemcel; marne-cel, a lentiviral vector-based investigational gene therapy for severe Leukocyte Adhesion Deficiency-I. The PDUFA date is March 28, 2026.
"We value the continued dialogue with the FDA and believe the BLA moves Rocket closer to our goal of delivering a one-time gene therapy to patients facing the devastating effects of severe LAD-I," said Gaurav Shah, CEO, Rocket Pharma.
Shares of Rocket Pharmaceuticals are up 8% in pre-market trade on Tuesday.
For More Such Health News, visit rttnews.com.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.